Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-64 years~* Duration of T1D ≥ 3 years~* Use of CSII or MDI therapy for ≥ 6 months~* Current use of Novorapid (change from another fast-acting insulin to Novorapid prior to study initiation is allowed)~* HbA1c ≤ 8.0%~* Regular use of carbohydrate counting in the judgement of the investigator~Exclusion Criteria:~* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start~* History of allergy or intolerance to glucagon or glucagon-like products~* Patients with pheochromocytoma~* Clinically significant ECG abnormalities~* Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (sterilization, intrauterine device, contraceptive pill, patch or injection)~* Inability to understand the individual information and to give informed consent~* Current participation in another clinical trial that, in the judgment of the principle investigator, will compromise the results of the study or the safety of the subject~* Other concomitant medical or psychological condition that, according to the investigator's assessment, makes the individual unsuitable for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 80 µg s.c. dasiglucagon (Type: EXPERIMENTAL): 80 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
- 120 µg s.c. dasiglucagon (Type: EXPERIMENTAL): 120 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
- 15 g oral carbohydrate (dextrose tablets) (Type: ACTIVE_COMPARATOR): 15 g of oral carbohydrate (dextrose tablets) will be administered when plasma glucose levels reach 4.5 mmol/l

Based on this trial design, predict the completion outcome and termination type (if applicable).